Background: Chronic obstructive pulmonary disease (COPD) has significant systemic
manifestations, including cardiovascular morbidity. The main aim of our study was to …

Background Long-acting bronchodilators are the cornerstone of pharmacologic treatment of
COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) …

In older adults, chronic obstructive pulmonary disease (COPD) is commonly associated with
heart failure with reduced ejection fraction (HFrEF), and the high prevalence of this …

The 3-min constant speed shuttle test (CSST) was used to examine the effect of
tiotropium/olodaterol compared with tiotropium at reducing activity-related breathlessness in …

Background The systemic inflammation is associated with clinical outcome and mortality in
chronic obstructive pulmonary disease (COPD) patients. To investigate the effects of …

Background Maintaining and improving physical functioning is key to mitigating the cycle of
deconditioning associated with chronic obstructive pulmonary disease (COPD). We …

Introduction Real-world evidence is needed to optimize pharmacotherapy for chronic
obstructive pulmonary disease (COPD). The effectiveness of inhaled tiotropium/olodaterol …

Dual bronchodilation therapy represents the cornerstone for the treatment of COPD. A large
retrospective study reports that adding a second long-acting bronchodilator in patients with …

Background Reduced physical activity is associated with increased morbidity and mortality
in patients with COPD. Studies suggest that treatment with the long-acting muscarinic …

Objective This meta-analysis was performed to evaluate the efficacy and safety of adding
fluticasone propionate/salmeterol (FSC) to tiotropium (Tio) in COPD patients. Methods A …